ALT 803

Drug Profile

ALT 803

Alternative Names: ALT-803; IL-15N72D:IL-15RαSu/Fc fusion protein complex

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altor BioScience Corporation; NantKwest
  • Developer Altor BioScience Corporation; Masonic Cancer Center; NantCell; NantKwest; University of Minnesota; University of South Carolina
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Bladder cancer
  • Phase II Acute myeloid leukaemia; Merkel cell carcinoma
  • Phase I/II Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer
  • Phase I HIV infections; Malignant melanoma
  • Preclinical Bacterial infections

Most Recent Events

  • 01 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03136406)
  • 27 Jul 2017 Altor Bioscience plans the QUILT-3.055 phase II trial for Non-small cell lung cancer(Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (NCT03228667)
  • 29 Jun 2017 NantCell plans the phase Ib/II QUILT-3.051 trial for Ovarian cancer (Combination therapy, Second-line therapy or greater) in September 2017 (NCT03197584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top